Compare GLU & LUCD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GLU | LUCD |
|---|---|---|
| Founded | 2004 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 116.8M | 132.4M |
| IPO Year | N/A | 2021 |
| Metric | GLU | LUCD |
|---|---|---|
| Price | $19.93 | $1.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $3.94 |
| AVG Volume (30 Days) | 12.4K | ★ 701.5K |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 8.60% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.62 | N/A |
| Revenue | N/A | ★ $4,399,000.00 |
| Revenue This Year | N/A | $11.18 |
| Revenue Next Year | N/A | $147.43 |
| P/E Ratio | $22.50 | ★ N/A |
| Revenue Growth | N/A | ★ 5.01 |
| 52 Week Low | $11.61 | $0.75 |
| 52 Week High | $15.40 | $1.80 |
| Indicator | GLU | LUCD |
|---|---|---|
| Relative Strength Index (RSI) | 78.75 | 47.31 |
| Support Level | $18.36 | $1.09 |
| Resistance Level | $18.65 | $1.15 |
| Average True Range (ATR) | 0.25 | 0.05 |
| MACD | 0.15 | 0.00 |
| Stochastic Oscillator | 85.96 | 37.04 |
Gabelli Global Utility & Income Trust is a non-diversified, closed-end management investment company. The Fund's objective is to seek a consistent level of after-tax total return. It predominantly invests in stocks of companies involved to a substantial extent in providing products, services, or equipment for the generation or distribution of electricity, gas, or water and infrastructure operations, and in equity securities including preferred securities of companies in other industries, in each case in such securities that are expected to pay periodic dividends.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.